ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy

Area of Science:

• Immunology
• Oncology
• Microbiome research

Background:

• The function of intestinal Group 3 innate lymphoid cells (ILC3s) in cancer development is not well understood.
• Innate lymphoid cells (ILCs) are crucial immune cells residing in various tissues, including the gut.
• ILC3s are known for their roles in maintaining intestinal homeostasis and responding to microbial signals.

Purpose of the Study:

• To investigate the plasticity and function of intestinal ILC3s within the tumor microenvironment.
• To explore how ILC3s may influence colorectal cancer (CRC) progression.
• To determine the potential impact of ILC3s on immunotherapy outcomes in cancer patients.

Main Methods:

• Analysis of ILC3 populations within tumor samples.
• Characterization of ILC phenotypes and functional states.
• Investigation of the interplay between ILC3s, tumor cells, and the gut microbiome.

Main Results:

• Intestinal ILC3s exhibit significant plasticity within tumors, altering their identity.
• These plastic ILC3s can differentiate into other ILC subtypes, such as ILC1s, or become exhausted.
• Altered ILC3 populations can reshape the gut microbiome composition.
• Changes in the gut microbiome driven by ILC3 plasticity are associated with colorectal cancer progression.
• ILC3 plasticity and associated microbiome changes correlate with resistance to cancer immunotherapy.

Conclusions:

• Intestinal ILC3s are plastic and can change their functional states within the tumor microenvironment.
• This ILC3 plasticity plays a role in promoting colorectal cancer progression.
• ILC3-mediated alterations of the gut microbiome contribute to immunotherapy resistance in colorectal cancer.